阿里巴巴:新增香港為主要上市地 將於8月28日完成雙重主要上市
今日,阿里巴巴集團發佈公吿,新增香港為主要上市地,將於8月28日在香港聯交所主板主要上市,成為在港交所、紐交所雙重主要上市的公司。
數據顯示,2019年阿里巴巴在香港第二上市以來,大部分公眾流通股已轉倉到香港,在市值和交易量方面,阿里一直位列港股前三名,主要上市水到渠成。2022年7月,阿里巴巴提出在香港主要上市的申請。在香港和紐約雙重主要上市,將進一步擴大投資者基礎,提升阿里港股的流動性,也為投資者在公開市場持有及交易阿里股份提供更大的靈活性。
據機構研報,新增香港為主要上市地後,阿里巴巴將符合納入港股通條件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.